ASLN ASLAN Pharmaceuticals Limited

1.53
+0.01  (+1%)
Previous Close 1.52
Open 1.56
52 Week Low 0.35
52 Week High 8.18
Market Cap $58,126,221
Shares 37,990,994
Float 37,990,994
Enterprise Value $62,272,548
Volume 24,805
Av. Daily Volume 75,498
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
ASLAN004
Atopic dermatitis
Phase 1
Phase 1
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
Varlitinib - TREETOPP
Biliary tract cancer
Phase 2/3
Phase 2/3
Phase 3 trial did not meet primary endpoint - November 11, 2019.
Varlitinib + mFOLFIRI
Solid tumors
Phase 1
Phase 1
Phase 1 presentation at ESMO September 28, 2019.
ASLAN003
Acute Myeloid Leukemia (AML)
Phase 2
Phase 2
Evaluating next steps - noted August 2019.
Varlitinib
Gastric cancer
Phase 2/3
Phase 2/3
Phase 2 trial did not meet primary endpoint - January 13, 2019.
Varlitinib + gemcitabine and cisplatin
Biliary tract cancer
Phase 1/2
Phase 1/2
Phase 1/2 new data presented at at ASCO Gastrointestinal Cancers Symposium January 2019.

Latest News

  1. SINGAPORE, Sept. 10, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced its presentation at the H.C. Wainwright 22nd Annual Global Investment Conference. Dr Carl Firth, Chief Executive Officer is scheduled to make a company presentation on 16 September 2020 at 9:00am EDT. The virtual conference will be held from 14-16 September 2020.

    The presentation deck used at the conference will be available in the Investors section of ASLAN's website at www.aslanpharma.com following the event.

    Media and IR contacts

    Emma Thompson
    Spurwing Communications
    Tel: +65 6751 2021
    Email:

    SINGAPORE, Sept. 10, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced its presentation at the H.C. Wainwright 22nd Annual Global Investment Conference. Dr Carl Firth, Chief Executive Officer is scheduled to make a company presentation on 16 September 2020 at 9:00am EDT. The virtual conference will be held from 14-16 September 2020.

    The presentation deck used at the conference will be available in the Investors section of ASLAN's website at www.aslanpharma.com following the event.

    Media and IR contacts

    Emma Thompson

    Spurwing Communications

    Tel: +65 6751 2021

    Email:  
    Robert Uhl

    Westwicke Partners

    Tel: +1 858 356 5932

    Email:

    About ASLAN Pharmaceuticals

    ASLAN Pharmaceuticals (NASDAQ:ASLN) is a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. Led by a senior management team with extensive experience in global development and commercialisation, ASLAN has a clinical portfolio comprised of a first in class monoclonal therapy, ASLAN004, that is being developed in atopic dermatitis and other immunology indications, and a small molecule inhibitor targeting oncology. ASLAN's partners include Almirall, Array BioPharma, Bristol-Myers Squibb, and CSL. For additional information please visit www.aslanpharma.com.

    Forward looking statements

    This release and the accompanying financial information, if any, contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of ASLAN Pharmaceuticals Limited and/or its affiliates (the "Company"). These forward-looking statements may include, but are not limited to, statements regarding the Company's business strategy, the Company's plans to develop and commercialise its product candidates, the safety and efficacy of the Company's product candidates, the Company's plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for the Company's product candidates. The Company's estimates, projections and other forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and inherently involve significant known and unknown risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation the risk factors described in the Company's U.S. Securities and Exchange Commission filings and reports (Commission File No. 001-38475), including the Company's Form 20-F filed with the U.S. Securities and Exchange Commission (the "SEC") on April 16, 2020.

    All statements other than statements of historical fact are forward-looking statements. The words "believe," "may," "might," "could," "will," "aim," "estimate," "continue," "anticipate," "intend," "expect," "plan," or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. Estimates, projections and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection or forward-looking statement.

    View Full Article Hide Full Article
  2. SINGAPORE, Aug. 24, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497))), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the resumption of patient recruitment into its randomised, double-blind, placebo-controlled multiple ascending dose (MAD) study of ASLAN004 in moderate to severe atopic dermatitis.

    ASLAN paused recruitment of new patients on 13 April 2020 in line with government restrictions enforced in Singapore to contain the spread of the coronavirus disease (COVID-19). Patients are now being recruited into the second of three dose cohorts at all screening sites in Singapore. To accelerate recruitment…

    SINGAPORE, Aug. 24, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497))), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the resumption of patient recruitment into its randomised, double-blind, placebo-controlled multiple ascending dose (MAD) study of ASLAN004 in moderate to severe atopic dermatitis.

    ASLAN paused recruitment of new patients on 13 April 2020 in line with government restrictions enforced in Singapore to contain the spread of the coronavirus disease (COVID-19). Patients are now being recruited into the second of three dose cohorts at all screening sites in Singapore. To accelerate recruitment, ASLAN is in the process of opening additional study sites in Australia and the US.

    ASLAN expects to report interim, unblinded data from all 3 dose cohorts in 4Q 2020.

    Media and IR contacts

    Emma Thompson

    Spurwing Communications

    Tel: +65 6751 2021

    Email:
    Robert Uhl

    Westwicke Partners

    Tel: +1 858 356 5932

    Email:

    About ASLAN Pharmaceuticals

    ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497))) is a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. Led by a senior management team with extensive experience in global development and commercialisation, ASLAN has a clinical portfolio comprised of a first in class monoclonal therapy, ASLAN004, that is being developed in atopic dermatitis and other immunology indications, and a small molecule inhibitor targeting oncology. ASLAN's partners include Almirall, Array BioPharma, Bristol-Myers Squibb, and CSL. For additional information please visit www.aslanpharma.com.

    Forward looking statements

    This release and the accompanying financial information, if any, contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of ASLAN Pharmaceuticals Limited and/or its affiliates (the "Company"). These forward-looking statements may include, but are not limited to, statements regarding the Company's business strategy, the Company's plans to develop and commercialise its product candidates, the safety and efficacy of the Company's product candidates, the Company's plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for the Company's product candidates. The Company's estimates, projections and other forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and inherently involve significant known and unknown risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation the risk factors described in the Company's U.S. Securities and Exchange Commission filings and reports (Commission File No. 001-38475), including the Company's Form 20-F filed with the U.S. Securities and Exchange Commission (the "SEC") on April 16, 2020.

    All statements other than statements of historical fact are forward-looking statements. The words "believe," "may," "might," "could," "will," "aim," "estimate," "continue," "anticipate," "intend," "expect," "plan," or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. Estimates, projections and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection or forward-looking statement.

     

    View Full Article Hide Full Article
  3. SINGAPORE, Aug. 07, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497))), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced its presentation at the BTIG Virtual Biotechnology Conference. Dr Carl Firth, Chief Executive Officer, and Stephen Doyle, Chief Business Officer, are scheduled to participate in a fireside chat on Monday, 10 August, 2020 at 09:00am ET. The conference will be held from 10-11 August 2020.

    The presentation deck used at the conference will be available in the Investors section of ASLAN's website at www.aslanpharma.com following the event.

    Ends

    Media and IR contacts

    Emma Thompson
    Spurwing

    SINGAPORE, Aug. 07, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497))), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced its presentation at the BTIG Virtual Biotechnology Conference. Dr Carl Firth, Chief Executive Officer, and Stephen Doyle, Chief Business Officer, are scheduled to participate in a fireside chat on Monday, 10 August, 2020 at 09:00am ET. The conference will be held from 10-11 August 2020.

    The presentation deck used at the conference will be available in the Investors section of ASLAN's website at www.aslanpharma.com following the event.

    Ends

    Media and IR contacts

    Emma Thompson

    Spurwing Communications

    Tel: +65 6751 2021

    Email:

    Robert Uhl

    Westwicke Partners

    Tel: +1 858 356 5932

    Email:

    About ASLAN Pharmaceuticals

    ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497))) is a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. Led by a senior management team with extensive experience in global development and commercialisation, ASLAN has a clinical portfolio comprised of a first in class monoclonal therapy, ASLAN004, that is being developed in atopic dermatitis and other immunology indications, and a small molecule inhibitor targeting oncology. ASLAN's partners include Almirall, Array BioPharma, Bristol-Myers Squibb, and CSL. For additional information please visit www.aslanpharma.com.

    Forward looking statements

    This release and the accompanying financial information, if any, contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of ASLAN Pharmaceuticals Limited and/or its affiliates (the "Company"). These forward-looking statements may include, but are not limited to, statements regarding the Company's business strategy, the Company's plans to develop and commercialise its product candidates, the safety and efficacy of the Company's product candidates, the Company's plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for the Company's product candidates. The Company's estimates, projections and other forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and inherently involve significant known and unknown risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation the risk factors described in the Company's U.S. Securities and Exchange Commission filings and reports (Commission File No. 001-38475), including the Company's Form 20-F filed with the U.S. Securities and Exchange Commission (the "SEC") on April 16, 2020. All statements other than statements of historical fact are forward-looking statements. 

    All statements other than statements of historical fact are forward-looking statements. The words "believe," "may," "might," "could," "will," "aim," "estimate," "continue," "anticipate," "intend," "expect," "plan," or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. Estimates, projections and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection or forward-looking statement. 

    View Full Article Hide Full Article
  4. SINGAPORE, Aug. 03, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497))), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that Dr Kenneth Kobayashi has been appointed Chief Medical Officer. Dr Kobayashi will be based in California and will be responsible for the global clinical development of ASLAN's pipeline, including the lead program, ASLAN004, an antibody that blocks the IL-13 receptor, which is being developed for atopic dermatitis (AD).

    Dr Kobayashi has more than 25 years of experience in drug development, clinical practice and regulatory affairs as a Dermatology expert. He most recently served as Senior…

    SINGAPORE, Aug. 03, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497))), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that Dr Kenneth Kobayashi has been appointed Chief Medical Officer. Dr Kobayashi will be based in California and will be responsible for the global clinical development of ASLAN's pipeline, including the lead program, ASLAN004, an antibody that blocks the IL-13 receptor, which is being developed for atopic dermatitis (AD).

    Dr Kobayashi has more than 25 years of experience in drug development, clinical practice and regulatory affairs as a Dermatology expert. He most recently served as Senior Medical Director at Dermira, a subsidiary of Eli Lilly, where he was responsible for the development of lebrikizumab, a monoclonal antibody for atopic dermatitis, and supported five Phase 3 registration studies together with preclinical and early clinical development for two novel compounds.

    Prior to joining Dermira, Dr Kobayashi was Clinical Development Medical Director at Novartis, in the Immunology, Hepatology and Dermatology Global Development Unit, where he supported the development programs for anti-IL-17C and anti-IgE monoclonal antibodies. He has also held senior and global leadership positions at LEO Pharma and was an Associate Professor, and Chair and Chief of the Division of Dermatology at the University of Ottawa and The Ottawa Hospital.

    Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals, said: "We are pleased to welcome Ken to our team and look forward to working with him as we plan for the late stage development of ASLAN004 in atopic dermatitis. He brings strong industry expertise and relationships from working on other novel biologics being developed for AD as well as his insights as a trained dermatologist. Ken's appointment is an important step for ASLAN as we build our presence in the US in order to execute our global Phase 2b program in 2021."

    Dr Ken Kobayashi, Chief Medical Officer, ASLAN Pharmaceuticals, commented: "I am very excited to join ASLAN and lead the global development of ASLAN004, a program I believe has the potential to be best-in-disease for atopic dermatitis and other indications.  I am looking forward to working closely with the team as we prepare for important clinical data readouts later this year from the ongoing multiple ascending dose study in AD and plan our move into additional indications."

    Dr Kobayashi completed his residency in Dermatology at the University of British Columbia and was a Chief Resident at the National Defence Medical Centre, Ottawa. He is an Adjunct Professor, Department of Medicine, at the University of Ottawa, and a fellow of the Royal College of Physicians and Surgeons of Canada and the American Academy of Dermatology. 

    Media and IR contacts

    Emma Thompson

    Spurwing Communications

    Tel: +65 6751 2021

    Email:  
    Robert Uhl

    Westwicke Partners

    Tel: +1 858 356 5932

    Email:
     

    About ASLAN Pharmaceuticals

    ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497))) is a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. Led by a senior management team with extensive experience in global development and commercialisation, ASLAN has a clinical portfolio comprised of a first in class monoclonal therapy, ASLAN004, that is being developed in atopic dermatitis and other immunology indications, and a small molecule inhibitor targeting oncology. ASLAN's partners include Almirall, Array BioPharma, Bristol-Myers Squibb, and CSL. For additional information please visit www.aslanpharma.com.

    Forward looking statements

    This release and the accompanying financial information, if any, contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of ASLAN Pharmaceuticals Limited and/or its affiliates (the "Company"). These forward-looking statements may include, but are not limited to, statements regarding the Company's business strategy, the Company's plans to develop and commercialise its product candidates, the safety and efficacy of the Company's product candidates, the Company's plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for the Company's product candidates. The Company's estimates, projections and other forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and inherently involve significant known and unknown risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation the risk factors described in the Company's U.S. Securities and Exchange Commission filings and reports (Commission File No. 001-38475), including the Company's Form 20-F filed with the U.S. Securities and Exchange Commission (the "SEC") on April 16, 2020. All statements other than statements of historical fact are forward-looking statements. 

    All statements other than statements of historical fact are forward-looking statements. The words "believe," "may," "might," "could," "will," "aim," "estimate," "continue," "anticipate," "intend," "expect," "plan," or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. Estimates, projections and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection or forward-looking statement. 

    View Full Article Hide Full Article
  5. SINGAPORE, July 17, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497))), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced further progress towards a primary listing on the Nasdaq Global Market ("Nasdaq") and receipt of a Notice of Delisting from the Taipei Exchange ("TPEx"), an expected step in the TPEx delisting process. The company will retain its listing of American Depositary Shares ("ADS") on Nasdaq in the United States and existing holders of ADS do not need to take any action as a result of this announcement.

    Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals, said: "Changing the company's

    SINGAPORE, July 17, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497))), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced further progress towards a primary listing on the Nasdaq Global Market ("Nasdaq") and receipt of a Notice of Delisting from the Taipei Exchange ("TPEx"), an expected step in the TPEx delisting process. The company will retain its listing of American Depositary Shares ("ADS") on Nasdaq in the United States and existing holders of ADS do not need to take any action as a result of this announcement.

    Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals, said: "Changing the company's primary listing to Nasdaq will enhance our ability to raise capital given the greater flexibility afforded to us when we are no longer subject to TPEx regulations. 90 percent of trading in our securities the last six months has taken place on Nasdaq and we have not raised any capital in Taiwan since 2017. This move is also in line with the shift in our commercial focus towards the U.S. market as we prepare to initiate a Phase 2b study of ASLAN004 in atopic dermatitis in 2021."

    ASLAN expects its ordinary shares to cease trading on TPEx on August 25, 2020, and TPEx regulations will cease to apply shortly thereafter. Holders of the company's ordinary shares can apply before September 25, 2020, to convert their shares into ADS and it is anticipated that the conversion will be completed before the end of October.

    ASLAN is currently recruiting patients into the second of three dose cohorts of its Phase 1 randomised, double-blind, placebo-controlled multiple ascending dose study of ASLAN004 in moderate to severe atopic dermatitis. Recruitment of patients into the study is expected to restart in August as restrictions put in place by the Singapore government to contain the spread of COVID-19 are gradually lifted. Sites in Australia and the U.S. are also preparing to come online to accelerate recruitment. The company expects to announce interim, unblinded data from the study in the fourth quarter of 2020.

    Further information is available on ASLAN's website via this link https://ir.aslanpharma.com/shareholder-faqs.  

    Ends

    Media and IR contacts

    Emma Thompson

    Spurwing Communications

    Tel: +65 6751 2021

    Email:
    Robert Uhl

    Westwicke Partners

    Tel: +1 858 356 5932

    Email:
     

    About ASLAN Pharmaceuticals

    ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497))) is a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. Led by a senior management team with extensive experience in global development and commercialisation, ASLAN has a clinical portfolio comprised of a first in class monoclonal therapy, ASLAN004, that is being developed in atopic dermatitis and other immunology indications, and a small molecule inhibitor targeting oncology. ASLAN's partners include Almirall, Array BioPharma, Bristol-Myers Squibb, and CSL. For additional information please visit www.aslanpharma.com.

    Forward looking statements

    This release and the accompanying financial information, if any, contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of ASLAN Pharmaceuticals Limited and/or its affiliates (the "Company"). These forward-looking statements may include, but are not limited to, statements regarding the potential delisting of the Company's ordinary shares from TPEx, including the timing of such delisting; the ability of the Company to develop and implement a plan to enable holders of the Company's ordinary shares to convert such securities into ADSs tradeable on Nasdaq; the potential benefits and financing ability of the Company as a result of a potential TPEx delisting or otherwise; and the Company's business strategy, the Company's plans to develop and commercialise its product candidates, the safety and efficacy of the Company's product candidates, the Company's plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for the Company's product candidates. The Company's estimates, projections and other forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and inherently involve significant known and unknown risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation the risk factors described in the Company's U.S. Securities and Exchange Commission filings and reports (Commission File No. 001-38475), including the Company's Form 20-F filed with the U.S. Securities and Exchange Commission (the "SEC") on April 16, 2020. All statements other than statements of historical fact are forward-looking statements.  

    All statements other than statements of historical fact are forward-looking statements. The words "believe," "may," "might," "could," "will," "aim," "estimate," "continue," "anticipate," "intend," "expect," "plan," or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. Estimates, projections and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection or forward-looking statement.

    View Full Article Hide Full Article
View All ASLAN Pharmaceuticals Limited News